Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03228394 · ClinicalTrials.gov registry record · Phase 2
A Clinical Trial of Intravenous (IV) Ganaxolone in Women With Postpartum Depression
A Phase 2 study, sponsored by Marinus Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 91
- Enrollment target
NCT03228394 is a Phase 2 study that has completed, run by Marinus Pharmaceuticals. The registered enrollment target is 91 participants.
The verdict
NCT03228394, a Phase 2 study, has completed, sponsored by Marinus Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 91 participants
- Enrollment target
Study Summary
This study will evaluate the Safety, Pharmacokinetics and Efficacy of IV Administration of Ganaxolone in Women with Postpartum Depression
Interventions
- DRUG Placebo
- DRUG Ganaxolone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 91 participants |
| Start Date | 2017-06-27 |
| Est. Completion | 2020-05-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03228394
The ClinicalTrials.gov registry entry for NCT03228394 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 91 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Marinus Pharmaceuticals, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03228394 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03228394 about?
NCT03228394 is a clinical study titled "A Clinical Trial of Intravenous (IV) Ganaxolone in Women With Postpartum Depression". This study will evaluate the Safety, Pharmacokinetics and Efficacy of IV Administration of Ganaxolone in Women with Postpartum Depression
What is the current status of trial NCT03228394?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 91 participants. The study started on 2017-06-27. Estimated completion is 2020-05-10.
What interventions are being tested in trial NCT03228394?
The interventions under investigation include: Placebo (DRUG), Ganaxolone (DRUG).
Who is sponsoring clinical trial NCT03228394?
This trial is sponsored by Marinus Pharmaceuticals, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.